EP4 receptor agonist, compositions and methods thereof

Abstract

This invention relates to potent selective agonists of the EP 4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.

1. A compound having the structural formula I: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt, enantiomer, diastereomer, prodrug or mixture thereof, wherein,
 Q is (CH 2 ) m , (CH 2 ) m C 6-10 aryl, (CH 2 ) m C 5-10  heterocyclyl, (CH 2 ) m C 3-10  heterocycloalkyl, (CH 2 ) m C 3-8  cycloalkyl, C(halo) 2 , said cycloalkyl, heterocycloalkyl, aryl or heterocyclyl unsubstituted or substituted with 1-3 groups of R a ; 
 X represents O, 
 Y represents CH 2 ; 
 U represents H, C1-3 alkyl or is not present when W is ═O; 
 W represents OH or ═O, provided that U is not present when W is ═O; 
 R 1  represents (CH 2 ) p hydroxy, (CH 2 ) p CN, (CH 2 ) p CO 2 R 10 , (CH 2 ) n SO 3 R 6 , —(CH 2 ) p CF 2 SO 2 NH 2 , —(CH 2 ) p SO 2 NH 2 , —(CH 2 ) p CONHSO 2 R 2  —(CH 2 ) p CONHSO 2 R 2 , —(CH 2 ) p SO 2 NHCOR 2 , —(CH 2 ) p PO(OH) 2 , (CH 2 ) p CONHPO 2 R 6 , (CH 2 ) p CONHR 8 , (CH 2 ) p C 1-4 alkoxy, —(CH 2 ) p cycloalkyl, or (CH 2 ) n heterocyclyl, said heterocyclyl unsubstituted or substituted with 1 to 3 groups of R a  and optionally containing an acidic hydroxyl group; 
 R 2  independently represents C 1-10  alkyl, (CH 2 ) m C 6-10 aryl, (CH 2 ) m C 5-10 heterocyclyl, (CH 2 ) m C 3-10  heterocycloalkyl, (CH 2 ) m C 3-8  cycloalkyl, O—C 1-10 alkyl, O—C 6-10 aryl, O—C 3-10 cycloalkyl, O—C 3-10 heterocycloalkyl, O—C 3-10  heterocycloalkyl, said alkyl, cycloalkyl, heterocycloalkyl, aryl or hetrocyclyl unsubstituted or substituted with 1-3 groups of R a ; 
 R 3  and R 4  independently represents hydrogen, halogen, or C 1-6  alkyl, or R 3  and R 4  may be taken together to form a 3-7 membered carbon ring optionally interrupted with 1-2 heteroatoms chosen from O, S, SO, SO 2 , and NR 9 ; 
 R 6  and R 7  independently represents hydrogen, or C 1-4  alkyl; 
 R 8  represents hydrogen, acyl, or sulfonyl; 
 R 9  represents hydrogen, C 1-6  alkyl, said alkyl optionally substituted with 1-3 halogen, CN, OH, C 1-6  alkoxy, C 1-6  acyloxy or amino; 
 R 10  represents hydrogen, C 1-10  alkyl, C 3-10  cycicoalkyl, (CH 2 ) p C 6-10  aryl, (CH 2 ) p C 5-10  heterocyclyl, CR 6 R 7 OC(O)O C 3-10  cycloalkyl or CR 6 R 7 OC(O)O C 1-10  alkyl; 
 Z represents a C≡C, O, S, (C(R b ) 2 ) n , or CH═CH; 
 R b  represents hydrogen, C 1-6  alkyl or halogen; 
 R a  represents C 1-6  alkoxy, C 1-6  alkyl, CF 3 , nitro, amino, cyano, C 1-6  alkylamino, halogen, SC 1-6 alkyl, SC 6-10 aryl, SC 5-10 heterocyclyl, CO 2 R 6 , OC 6-10 aryl, OC 5-10 heterocyclyl, CH 2 OC 1-6  alkyl, CH 2 SC 1-6  alkyl, CH 2 Oaryl, CH 2 Saryl; 
    represents a double or single bond; 
 p represents 0-3; 
 n represents 0-4; and 
 m represents 0-8. 
 
     
     
       2. A compound in accordance with  claim 1  wherein R 1  is (CH 2 ) p CN, (CH 2 ) p CO 2 R 10 , —(CH 2 ) p PO(OH) 2 , (CH 2 ) p CONHPO 2 R 6 , (CH 2 ) p CONHR 8 , or (CH 2 ) n heterocyclyl, said heterocyclyl unsubstituted or substituted with 1 to 3 groups of R a  and all other variables are as originally described. 
     
     
       3. A compound in accordance with  claim 2  wherein Z is a bond or S, Y is CH 2  and X is O, S or CH 2 . 
     
     
       4. A compound in accordance with  claim 1  wherein R 1  is (CH 2 ) p CO 2 R 10 , X is O, Y are is CH 2 , Z is (C(R b ) 2 ) n , Q is (CH 2 )m, and R 2  is (CH 2 ) m C 6-10 aryl, said aryl unsubstituted or substituted with 1 to 3 groups of R a . 
     
     
       5. A compound in accordance with  claim 2  wherein R 1  is (CH 2 ) m C 5-10 heterocyclyl, U is H, or C 1-3  alkyl, W is OH, Z is a bond or S, R 2  is (CH 2 ) m C 6-10 aryl, said aryl unsubstituted or substituted with 1 to 3 groups of R a , said heterocyclyl unsubstituted or substituted with 1 to 3 groups of R a  and all other variables are as originally described. 
     
     
       6. A compound which is:
 7-{(4S)-4-[(3R)-3-hydroxy-4-phenylbutyl]-2-oxo-1,3-oxazinan-3-yl}heptanoic acid; 
 5-(3-{(4R)-4-[(1E,3S)-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazinan-3-yl}propyl)thiophene-2-carboxylic acid; 
 isopropyl 5-(3-{(4R)-4-[(1E,3S)-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazinan-3-yl}propyl)thiophene-2-carboxylate; 
 7-{(4R)-4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazinan-3-yl}heptanoic acid; 
 7-{(4S)-4-[(3R)-4,4-difluoro-3-hydroxy-4-phenylbutyl]-2-oxo-1,3-oxazinan-3-yl}heptanoic acid; 
 isopropyl 7-{(4R)-4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazinan-3-yl}heptanoate; 
 (4R)-4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-[6-(2H-tetraazol-5-yl)hexyl]-1,3-oxazinan-2-one; 
 5-(3-{(4R)-4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazinan-3-yl}propyl)thiophene-2-carboxylic acid; 
 (4R)-4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-3-{3-[5-(2H-tetraazol-5-yl)thien-2-yl]propyl}-1,3-oxazinan-2-one; 
 (4S)-4-[(3R)-4,4-difluoro-3-hydroxy-4-phenylbutyl]-3-{3-[5-(2H-tetraazol-5-yl)thien-2-yl]propyl}-1,3-oxazinan-2-one; 
 isopropyl 5-(3-{(4R)-4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazinan-3-yl}propyl)thiophene-2-carboxylate; 
 (5E)-7-{(4R)-4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazinan-3-yl}hept-5-enoic acid; 
 (5E)-7-{(4S)-4-[(3R)-4,4-difluoro-3-hydroxy-4-phenylbutyl]-2-oxo-1,3-oxazinan-3-yl}hept-5-enoic acid; 
 Isopropyl-7-{(4R)-4-[(1E)-4,4-difluoro-3-hydroxy-4-phenylbut-1-en-yl]-2-oxo-1,3-oxanzinan-3-yl}heptanoate; 
 7-{(4R)-4-[(1E)-4,4-difluoro-3-hydroxy-4-phenylbut-1-en-yl]-2-oxo-1,3-oxanzinan-3-yl}heptanoic acid; 
 
       or a pharmaceutically acceptable salt, enantiomer, diastereomer, prodrug or mixture thereof. 
     
     
       7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I, as recited in  claim 1 . 
     
     
       8. A method for treating ocular hypertension or glaucoma comprising administration to a patient in need of such treatment a therapeutically effective amount of a compound of  claim 1 , said compound administered in a topical formulation as a solution or suspension. 
     
     
       9. A method for treating macular edema or macular degeneration, treating dry eye, increasing retinal and optic nerve head blood velocity, increasing retinal and optic nerve oxygen tension, comprising administration to a patient in need of such treatment a pharmaceutically effective amount of a compound of a compound as recited in  claim 1 . 
     
     
       10. The method according to  claim 9  in which the topical formulation optionally contains xanthan gum or gellan gum. 
     
     
       11. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula I, as recited in claim 6. 
     
     
       12. The compound according to claim 6 which is: 7-{(4S)-4-[(3R)-3-hydroxy-4-phenylbutyl]-2-oxo-1,3-oxazinan-3-yl}heptanoic acid or a pharmaceutically acceptable salt, enantiomer, diastereomer, or mixture thereof. 
     
     
       13. The compound according to claim 6 which is 5-(3-{(4R)-4-[(1E,3S)-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazinan-3-yl}propyl)thiophene-2-carboxylic acid or a pharmaceutically acceptable salt, enantiomer, diastereomer, or mixture thereof. 
     
     
       14. The compound according to claim 6 which is isopropyl 5-(3-{(4R)-4-[(1E,3S)-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazinan-3-yl}propyl)thiophene-2-carboxylate or a pharmaceutically acceptable salt, enantiomer, diastereomer, or mixture thereof. 
     
     
       15. The compound according to claim 6 which is 7-{(4R)-4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazinan-3-yl}heptanoic acid; 7-{(4S)-4-[(3R)-4,4-difluoro-3-hydroxy-4-phenylbutyl]-2-oxo-1,3-oxazinan-3-yl}heptanoic acid or a pharmaceutically acceptable salt, enantiomer, diastereomer, or mixture thereof. 
     
     
       16. The compound according to claim 6 which is isopropyl 7-{(4R)-4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazinan-3-yl}heptanoate or a pharmaceutically acceptable salt, enantiomer, diastereomer, or mixture thereof. 
     
     
       17. The compound according to claim 6 which is (5E)-7-{(4R)-4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-2-oxo-1,3-oxazinan-3-yl}hept-5-enoic acid or a pharmaceutically acceptable salt, enantiomer, diastereomer, or mixture thereof. 
     
     
       18. The compound according to claim 6 which is (5E)-7-{(4S)-4-[(3R)-4,4-difluoro-3-hydroxy-4-phenylbutyl]-2-oxo-1,3-oxazinan-3-yl}hept-5-enoic acid or a pharmaceutically acceptable salt, enantiomer, diastereomer, or mixture thereof. 
     
     
       19. The compound according to claim 6 which is Isopropyl-7-{(4R)-4-[(1E)-4,4-difluoro-3-hydroxy-4-phenylbut-1-en-yl]-2-oxo-1,3-oxanzinan-3-yl}heptanoate or a pharmaceutically acceptable salt, enantiomer, diastereomer, or mixture thereof. 
     
     
       20. The compound according to claim 6 which is 7-{(4R)-4-[(1E)-4,4-difluoro-3-hydroxy-4-phenylbut-1-en-yl]-2-oxo-1,3-oxanzinan-3-yl}heptanoic acid or a pharmaceutically acceptable salt, enantiomer, diastereomer, or mixture thereof.